Information Provided By: 
Fly News Breaks for May 31, 2019
ADAP
May 31, 2019 | 08:31 EDT
Roth Capital analyst Tony Butler initiated Adaptimmune with a Buy rating and $7 price target, stating that the company has a differentiated and highly optimized approach to developing T-cell receptors and has shown strong early-stage data in synovial sarcoma. He also thinks ADP-A2M4 could demonstrate promising data in esophageal cancer, Butler tells investors.
News For ADAP From the Last 2 Days
There are no results for your query ADAP
